Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1459 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Onyx Pharma to delay Carfilzomib NDA filing

FDA has requested additional CMC information related to commercial-scale manufacturing of Carfilzomib. Onyx had previously anticipated filing an NDA by the end of 2010 for accelerated approval of

Roxane Laboratories ANDA gets FDA nod

The strengths of Losartan Potassium tablets USP approved by FDA are 25mg, 50mg and 100mg while that of Losartan Potassium and Hydrochlorothiazide tablets are 50mg/12.5mg and 100mg/25mg. Roxane

Prima BioMed names new chairman

Turnbull has played different roles in her career including chairman of the New South Wales Government’s Ministerial Advisory Committee on Biotechnology (2001-2), a director of the Sydney Cancer